UBS has given Carl Zeiss Meditec a "Neutral" rating with a target price of 65 euros.
Analyst Graham Doyle has expressed concerns about the European medical technology sector, which has underperformed the overall market this year.
Doyle's analysis shows that his sales and earnings forecasts for 2025 are lower than the consensus estimates for 10 out of the 17 sector stocks he covers.
This skepticism reflects the challenges faced by the industry, as highlighted in a recent industry commentary.
The report emphasizes the cautious outlook for medical technology shares and advises investors to remain vigilant in the current market environment.